We help Support at Home-approved families find care.
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

Drug to battle septic shock

Posted
by DPS

Australian scientists say they have developed a drug that may stop people from dying of septic shock after surgery. Tests on animals had shown the medication could halt kidney failure brought on by post-operative complications.

Dr Clive May of Melbourne’s Howard Florey Institute said kidney failure had been the most deadly side effect but treatments were inadequate.

Working with colleagues at Austin Hospital in Victoria, the researchers studied the basic mechanisms of kidney injury and tested therapies on lab animals. Late last year they began human trials with one so far unnamed drug, giving it to a handful of shock patients with deteriorating renal function.

“Results from the first patient are very encouraging … and we’re obviously hoping this will be an important advance,” Dr May said.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo